Canadian export playbooks tend to stop at three destinations. Germany, Australia and Israel absorb most of what leaves this country, and nearly every compliance guide written for a Licensed Producer is calibrated to those three regimes.
Emerging cannabis import markets are the second tier of jurisdictions that already run a working import pathway, a named competent authority and a real patient base, but draw far less Canadian supply. Four are worth screening in 2026: Poland, Czechia, Switzerland and Brazil. Three of them will take dried flower. One will not, and that single distinction decides whether a market deserves an hour of your regulatory team's time.
The common mistake is reading patient count as market size. Brazil has more registered medical cannabis patients than any country in Latin America, and a Canadian flower producer still cannot sell a gram of dried flower into its commercial channel.
Where the emerging cannabis import markets stand in 2026
Every one of these markets runs on the same underlying architecture: a Health Canada export permit issued under the Cannabis Act, matched to an import authorisation from the destination regulator. What changes between them is who issues that authorisation, what it attaches to, and whether your product form is admissible at all. If the sequencing is new to you, start with how the two-permit chain works.
| Market | Import authority | What the authorisation attaches to | Quality standard expected | Dried flower admissible | Who pays |
|---|---|---|---|---|---|
| Poland | GIF, with URPL | Per shipment, plus a product authorisation | EU-GMP | Yes | Patient, no reimbursement |
| Czechia | SUKL, via SAKL | Import licence plus narcotics handling permit | EU-GMP | Yes | Insurance, up to 90 percent |
| Switzerland | Swissmedic | Single Permit per consignment | Swissmedic licensing, GMP evidence | Yes | Mixed, assessed case by case |
| Brazil | ANVISA | Sanitary Authorisation held by a local entity | PIC/S recognised GMP | No | Patient, out of pocket |
| Germany (reference) | BfArM | Per consignment narcotic import permit | EU-GMP | Yes | Statutory and private insurance |
Read that table as a filter rather than a ranking, measured against the German requirements most Canadian LPs already work to. Poland moves the most flower of the four. Czechia pays the best per gram because the state carries most of the cost. Switzerland has the tightest permit clock. Brazil has the patients and the wrong product category. For a side by side view of what each of these regimes wants on the certificate of analysis, see our breakdown of export testing requirements across four markets.
Poland is Europe's largest import-led flower market
Polish pharmacies dispensed close to 5,450 kg of dried cannabis flower in 2025, a volume increase of roughly 12 percent year over year. Revenue moved the other way. Full-year value fell about 19 percent to approximately 253 million PLN, according to market analysis published by Cannabis Industry Data. More grams, less money per gram. That is a price-compressing market, and any Canadian supplier quoting into it should price accordingly.
Poland is import-led by design. A 2022 amendment to the Act on Counteracting Drug Addiction allowed domestic cultivation, but only by research institutions holding a permit from the Chief Pharmaceutical Inspector. One permit has been granted, to the Warsaw Institute of Biotechnology in December 2023, and domestic output has not materially reached pharmacy shelves. Practically speaking, every gram a Polish patient receives arrives from abroad.
The product authorisation is the real bottleneck
Two separate approvals gate a Polish shipment, and they are not equally difficult. The Office for Registration of Medicinal Products, known as URPL, issues a marketing authorisation for cannabis raw material tied to a named supplier. It runs for five years, and applicants have historically waited well past two years for a decision. Your Polish partner's existing authorisations are the commercial asset, not their warehouse.
The shipment permit is comparatively routine. The Chief Pharmaceutical Inspectorate, or GIF, issues import authorisations on a per-shipment basis to applicants already holding the appropriate wholesale or manufacturing licence. Around 30 authorised flower products currently sit on the Polish market.
What that means for a Canadian supplier
Three questions belong in your first call with a Polish wholesaler:
- Which URPL marketing authorisations do you already hold, and for which suppliers?
- Are you seeking a new authorisation for our material, and who files it?
- What is your realistic timeline from signed supply agreement to first dispensed gram?
Product supplied into Polish pharmacies must meet EU-GMP requirements, which in practice means your flower is released by a Qualified Person inside the European Economic Area before it reaches a pharmacy. The mechanics of that handoff are covered in our guide to EU QP batch release for Canadian LPs.
One structural risk is worth pricing in. Poland restricted telemedicine prescribing for medical cannabis in November 2024, and prescription volumes fell 54 percent within two months. Volumes recovered through in-person consultations and by December 2025 had passed the pre-restriction peak, but the episode showed how quickly a single ministerial decision can reset demand in a cash-pay market.
Czechia and Switzerland trade volume for margin
Neither market will absorb tonnage. Both pay better than Poland per gram, and both are structurally short of domestic supply.
Czechia: reimbursed, regulated, and importing
Czechia legalised medical cannabis in 2013. The State Institute for Drug Control, SUKL, licenses import and manufacturing, while the State Agency for Medical Cannabis administers the programme itself. A commercial operator needs both a permit to handle addictive substances and an authorisation for its specific activity, whether that is import, distribution or cultivation.
The economics differ from Poland's in one decisive way. Since a 2020 reform, Czech patients have been reimbursed up to 90 percent of the cost within monthly limits, and may be prescribed up to 30 grams per month. A reimbursed market is far less price-elastic than a cash market, so buyers there are more willing to pay for consistency and documentation quality.
Access has also widened. Since April 2025, general practitioners have been able to prescribe cannabis for chronic pain, which previously sat with specialists only, and the registered prescriber base has grown to roughly 296 doctors. Domestic supply has not kept pace. Ten cultivators hold SUKL licences, but the largest of them, Lagom Pharmatech, exports the majority of its production to Germany, and only around 200 kg reached Czech pharmacies from that source.
Switzerland: outside the EU, and on a four-month clock
Swiss rules changed on 1 August 2022, when cannabis containing 1.0 percent THC or more moved to Table a of the narcotics ordinance. That removed the old requirement for exceptional authorisations from the Federal Office of Public Health and put the category under a structured licensing regime. Swissmedic now functions as the national Cannabis Agency under the Single Convention on Narcotic Drugs.
Import and export both run on a Single Permit issued by Swissmedic. Two features of that permit shape supply planning. Validity is short, generally around four months, and every transaction must be reported within ten working days. Your cultivation, testing and release schedule needs to be locked before the permit is issued, not negotiated afterwards.
Switzerland sits outside the European Union, so an EU-GMP certificate does not automatically satisfy Swissmedic. Swiss counterparties hold their own narcotics authorisation for Table A substances alongside an establishment licence, and flower, extracts, oils, tinctures and resins are all handled as controlled medicines. Flower is admissible, which is more than can be said for the largest market on this list.
Brazil and the four-gate market screen
Brazil has more than 873,000 registered medical cannabis patients and a domestic market that analysts expect to approach R$1 billion in 2026. On patient count alone it dwarfs Czechia and Switzerland combined. It is also the market a Canadian dried flower producer should screen out fastest.
ANVISA replaced the provisional RDC 327/2019 framework with RDC 1,015/2026, which took effect on 4 May 2026 after seven years of interim rules. The accompanying cultivation and regulatory sandbox resolutions, RDC 1,012, 1,013 and 1,014, followed on 4 August 2026. The new framework is permanent, more generous on patient access, and considerably stricter on manufacturing.
Here is the part that matters commercially. The authorised commercial category covers industrialised products containing exclusively cannabidiol or extracts of Cannabis sativa L. Dried flower in natura is not an approved product form for the Brazilian commercial channel. A separate route under RDC 660/2022 lets individual patients import finished products with a prescription and prior ANVISA registration. Roughly 600 products from more than 500 companies are listed there, with the United States as the leading source country and Canada close behind. That pathway sells finished goods to patients, not bulk flower to distributors.
Structure adds a second barrier. A foreign company cannot hold the authorisation itself. Supply runs through a Brazilian entity holding the Sanitary Authorisation, an operating licence and a special authorisation, and Brazil's membership of PIC/S means PIC/S recognised GMP certification carries weight there. For an LP whose product is hand-trimmed flower, Brazil is an extract and active ingredient conversation, not a flower conversation.
The four-gate market screen
Brazil is a useful teaching case because the disqualifying fact sits at gate one, before any of the commercial diligence that usually consumes a business development cycle. Run every new destination through these four gates in order, and stop at the first failure:
- Product form. Is your actual SKU an authorised category in that market, or only its derivatives? Answer this before anything else.
- Quality standard. Which GMP does the destination regulator recognise, and does your existing certificate satisfy it without a new audit?
- Permit architecture. Does authorisation attach to the consignment, the product, the supplier, or all three? Who files, and how long does each layer take?
- Payer. Statutory insurance, private insurance or cash. Cash markets compress price faster and react harder to prescribing rule changes.
Most Canadian LPs run these gates in reverse, starting with market size and working backwards to compliance. That ordering is why business development teams spend quarters on markets their product cannot legally enter.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower with refined genetics and full batch traceability. We hold export authorisation under the Cannabis Act and maintain the ISO/IEC 17025 tested batch data and documentation records that pharmacy-supplied European import markets such as Poland, Czechia and Switzerland expect from a Canadian supply partner.
If you are a licensed importer or wholesaler in one of these markets, the fastest way to start is to tell us which authorisations you already hold and which specification you are filling. Send us your requirements and we will tell you whether our current batches fit before either side spends time on paperwork.
Frequently Asked Questions
Which countries import Canadian cannabis flower besides Germany and Australia?
Israel is the third established destination for Canadian flower. Beyond those three, Poland, Czechia and Switzerland all operate functioning import pathways that admit dried flower, and Poland is the largest of them by dispensed volume. Each requires a Health Canada export permit matched to an import authorisation from the destination regulator.
Does Poland require a separate permit for every cannabis shipment?
Yes. The Chief Pharmaceutical Inspectorate, GIF, issues import authorisations on a per-shipment basis to applicants already holding the appropriate wholesale or manufacturing licence. A separate URPL marketing authorisation, tied to a named supplier and valid for five years, must also be in place before the product can be dispensed.
Can a Canadian Licensed Producer sell dried cannabis flower in Brazil?
Not through the commercial channel. Under ANVISA resolution RDC 1,015/2026, which took effect on 4 May 2026, authorised commercial products must be industrialised and contain exclusively cannabidiol or extracts of Cannabis sativa L. Dried flower in natura is not an approved product form, so Brazil is an extract and active ingredient market for Canadian suppliers rather than a flower market.
Is EU-GMP certification enough to supply Switzerland?
No. Switzerland is outside the European Union, so an EU-GMP certificate does not automatically satisfy Swissmedic, which acts as the national Cannabis Agency. Swiss counterparties must hold a narcotics authorisation for Table A substances plus an establishment licence, and Swissmedic assesses quality evidence on its own terms.
How long is a Swiss cannabis import permit valid?
Swissmedic issues a Single Permit for each import or export transaction, and validity is generally around four months. Every transaction must also be reported to Swissmedic within ten working days, so production and batch release schedules need to be confirmed before the permit is issued.
Which emerging cannabis market reimburses patients for medical cannabis?
Czechia is the strongest reimbursed market of the four. Since a 2020 reform, Czech patients have been reimbursed up to 90 percent of the cost within monthly limits and may be prescribed up to 30 grams per month. Poland and Brazil are cash-pay markets with no reimbursement, which makes them considerably more price-sensitive.
